Hybio Pharmaceutical
Hybio Pharmaceutical Co., Ltd. engages in the research, development, production, and marketing of peptide and oligonucleotide drugs in China and internationally. The company offers finished dosage form (FDF) products for obstetrics and gynecology, haemostatic agent, digestive tract and metabolic systems, immune system modulation, cardiovascular, diabetes mellitus, and osteoporosis, as well as dis… Read more
Hybio Pharmaceutical (300199) - Total Assets
Latest total assets as of September 2025: CN¥3.17 Billion CNY
Based on the latest financial reports, Hybio Pharmaceutical (300199) holds total assets worth CN¥3.17 Billion CNY as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Hybio Pharmaceutical - Total Assets Trend (2007–2024)
This chart illustrates how Hybio Pharmaceutical’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Hybio Pharmaceutical - Asset Composition Analysis
Current Asset Composition (December 2024)
Hybio Pharmaceutical's total assets of CN¥3.17 Billion consist of 15.4% current assets and 84.6% non-current assets.
| Asset Category | Amount (CNY) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 3.2% |
| Accounts Receivable | CN¥104.90 Million | 3.5% |
| Inventory | CN¥238.63 Million | 7.9% |
| Property, Plant & Equipment | CN¥0.00 | 0.0% |
| Intangible Assets | CN¥430.09 Million | 14.3% |
| Goodwill | CN¥0.00 | 0.0% |
Asset Composition Trend (2007–2024)
This chart illustrates how Hybio Pharmaceutical's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Hybio Pharmaceutical's current assets represent 15.4% of total assets in 2024, a decrease from 64.1% in 2007.
- Cash Position: Cash and equivalents constituted 3.2% of total assets in 2024, up from 3.1% in 2007.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 14.0% of total assets, an increase from 0.0% in 2007.
- Asset Diversification: The largest asset category is intangible assets at 14.3% of total assets.
Hybio Pharmaceutical Competitors by Total Assets
Key competitors of Hybio Pharmaceutical based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Swedish Orphan Biovitrum AB (publ)
PINK:BIOVF
|
USA | $67.26 Billion |
|
Kamada
NASDAQ:KMDA
|
USA | $378.79 Million |
|
One World Pharma Inc
OTCQB:OWPC
|
USA | $6.62 Million |
|
Dongwha Pharm.Co.Ltd
KO:000020
|
Korea | ₩654.63 Billion |
|
Shenzhen Neptunus Bioengineering Co Ltd
SHE:000078
|
China | CN¥27.28 Billion |
|
Yuhan Corp.
KO:000100
|
Korea | ₩3.05 Trillion |
|
Anhui Fengyuan Pharmaceutical Co Ltd
SHE:000153
|
China | CN¥4.97 Billion |
|
Kotra Industries Bhd
KLSE:0002
|
Malaysia | RM363.90 Million |
Hybio Pharmaceutical - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Hybio Pharmaceutical generates 0.20x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Hybio Pharmaceutical is currently not profitable relative to its asset base.
Hybio Pharmaceutical - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.37 | 0.43 | 0.95 |
| Quick Ratio | 0.18 | 0.23 | 0.78 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CN¥-951.59 Million | CN¥ -737.61 Million | CN¥ -49.98 Million |
Hybio Pharmaceutical - Advanced Valuation Insights
This section examines the relationship between Hybio Pharmaceutical's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 24.90 |
| Latest Market Cap to Assets Ratio | 0.53 |
| Asset Growth Rate (YoY) | -8.2% |
| Total Assets | CN¥3.01 Billion |
| Market Capitalization | $1.60 Billion USD |
Valuation Analysis
Below Book Valuation: The market values Hybio Pharmaceutical's assets below their book value (0.53 x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Hybio Pharmaceutical's assets decreased by 8.2% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Hybio Pharmaceutical (2007–2024)
The table below shows the annual total assets of Hybio Pharmaceutical from 2007 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥3.01 Billion | -8.21% |
| 2023-12-31 | CN¥3.28 Billion | -9.25% |
| 2022-12-31 | CN¥3.61 Billion | -7.56% |
| 2021-12-31 | CN¥3.91 Billion | -2.83% |
| 2020-12-31 | CN¥4.02 Billion | -14.91% |
| 2019-12-31 | CN¥4.72 Billion | -16.53% |
| 2018-12-31 | CN¥5.66 Billion | +6.84% |
| 2017-12-31 | CN¥5.30 Billion | +18.87% |
| 2016-12-31 | CN¥4.46 Billion | +25.69% |
| 2015-12-31 | CN¥3.55 Billion | +108.90% |
| 2014-12-31 | CN¥1.70 Billion | +31.72% |
| 2013-12-31 | CN¥1.29 Billion | +14.71% |
| 2012-12-31 | CN¥1.12 Billion | +8.48% |
| 2011-12-31 | CN¥1.04 Billion | +386.48% |
| 2010-12-31 | CN¥212.89 Million | +16.67% |
| 2009-12-31 | CN¥182.47 Million | +33.63% |
| 2008-12-31 | CN¥136.55 Million | +134.46% |
| 2007-12-31 | CN¥58.24 Million | -- |